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Abstract— Studies have implicated ceramide as a key 
molecular agent in regulating programmed cell death, or 
apoptosis. Consequently, there is significant potential in 
targeting intracellular ceramide as a cancer therapeutic 
agent. The cell’s major ceramide source is the ceramide 
de novo synthesis pathway, which consists of a complex 
network of interdependent enzyme-catalyzed biochemical 
reactions. To understand how ceramide works, we have 
initiated the study of the ceramide de novo synthesis 
pathway using computational modeling based on 
fundamental principles of biochemical kinetics.  
Specifically, we designed and developed the model in 
MATLAB SIMULINK for the behavior of 
dihydroceramide desaturase. Dihydroceramide desaturase 
is one of three key enzymes in the ceramide de novo 
synthesis pathway, and it converts a relatively inert 
precursor molecule, dihydroceramide into biochemically 
reactive ceramide. A major issue in modeling is parameter 
estimation. We solved this problem by adopting a 
heuristic strategy based on a priori knowledge from 
literature and experimental data. We evaluated model 
accuracy by comparing the model prediction results with 
interpolated experimental data.  Our future work includes 
more experimental validation of the model, dynamic rate 
constants assessment, and expansion of the model to 
include additional enzymes in the ceramide de novo 
synthesis pathway. 
I. INTRODUCTION 
eramide is implicated in cell apoptosis, making it 
a viable candidate for cancer research [1].  The 
ceramide de novo synthesis pathway is a major 
source of ceramide in the cell.  Building a model 
to describe ceramide de novo synthesis pathway will 
facilitate experimental scientists to optimize experimental 
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design in the lab.  In the long term, it will help predict the 
effects of a particular drug on the ceramide de novo 
synthesis pathway, and improve disease prognosis and 
treatment as a form of patient-customized medicine.  
II. BIOLOGICAL MOTIVATION 
Ceramide is a sphingolipid that plays a key role in 
apoptosis, or programmed cell death [1, 2]. Ceramide is 
generated from one of two major pathways: (a) ceramide 
catabolism from molecules such as sphingomyelin and (b) 
the ceramide de novo synthesis pathway, which produces 
ceramide from serine and palmitoyl-coA.    Production of 
certain ceramides, such as those with a length 16 fatty 
acyl chain (ceramide-16) [3], is known to increase 
cytotoxicity. Intracellular metabolic response to external 
stimuli such as heat shock and exposure to chemotherapy 
have been associated with increased levels of pro-
apoptotic ceramides [4, 5]. As such, ceramide has the 
potential to provide selective toxicity to malignant cells, 
and is a potentially significant target for cancer research 
[1-2, 4-6]. Thus, understanding the dynamics of the ceramide 
de novo synthesis pathway is imperative for unleashing its 
cancer-fighting power.  
 
 
Figure 1. Digram of ceramide de novo synthesis pathway. 
“Star” labels reactions that are catalyzed by the enzyme 
dihydroceramide desaturase. “E” denotes “dihydroceramide 
desaturase”. 
III. METHODS 
A. Modeling the ceramide de novo synthesis pathway  
For this study, we focused on one specific reaction in the 
ceramide de novo synthesis pathway, the desaturation 
reaction of dihydroceramide-16 (DHCer) into ceramide-
16 (Cer) that is catalyzed by the enzyme dihydroceramide 
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desaturase.  This specific reaction is highlighted in the 
pathway shown in Figure 1.   
 
B. Michaelis-Menten & the King-Altman algorithm 
The triangular-form mechanism shown in Figure 2 was 
constructed using Michaelis-Menten kinetics combined 
with the King-Altman algorithm[7,8]. DHCer is designated 
as substrate (S), Cer is designated as product (P), and 
dihydrosphingomyelin (DHSM) is designated as inhibitor 
(I). DHSM was assumed to be the sole inhibitor of the 
reaction based on the structural similarity between DHSM 
and DHCer, especially with regards to the size of the 
functional head-group[9].   
 
 
Figure 2. King-Altman geometric representation of an 
enzymatic reaction model with competitive inhibition. S = 
substrate  DHCer, P = product, Cer, and I = inhibitor DHSM, ES 
= enzyme-substrate complex, EP = enzyme-product complex, EI 
= enzyme-inhibitor complex, ki's = rate constants 
 
Based on Figure 2, reaction rate equations 1-4 were 
derived as follows, where, Eo = total enzyme 
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Equations 5-7 were then derived from Figure 2 to 
describe the rates of change of substrate [S], product [P] 
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Equations 1-4 were then substituted into equations 5-7, 
yielding equations 8-10. This was a necessary because 
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C.  Experimental Data Acquisition 
In vivo data on ceramide concentration dynamics was 
obtained over six hours at one hour intervals by the 
Georgia Tech Sphingolipid Research Laboratory using 
LC-MS/MS mass spectrometry. This data is the basis for 
initial model conditions listed in Table I. Cubic spline 
interpolation was performed on the mass spectrometry 
data to establish a basis for model validation.   
D.  Parameter Estimation 
Table II summarizes physical embodiments of the model 
rate constants, the values which were chosen to model 
them, and the basis for their choice. k3 and k6, were 
chosen based on a priori knowledge, and the remainder 
of constants were chosen based on physical assumptions. 
E.  Simulation 
Equations 8-10 were implemented in Matlab Simulink as 
shown in Figure 3 using initial conditions from Table I 
and parameter values from Table II.  Product and 
substrate concentrations were tracked over a period of 
simulation-time units equivalent to six hours real-time.  
 
Table I. Model initial conditions 
 
Biological Species Initial Concentration (pmol/mg protein) 
Ceramide (Cer) 98.340000000E-12 
Dihydroceramide (DHCer) 4.630417394E-11  
Dihydrospingomyelin (DHSM) 1.927537263E-7 
IV. RESULTS 
Cubic spline interpolated mass spectrometry data was 
graphically overlaid on simulation results, as shown in 












concentration with time (trend unobserved at presented 
scale) and a much faster concurrent linear decrease in 
DHCer concentration. Interpolated experimental data, 
represented by the dotted line in Figure 4, revealed that, 
in general, Cer concentration does actually increase with 
time but at a nonlinear rate.  
 
Table II. Physical embodiments & basis for estimation of rate constants 
 
Rate Constant Physical Embodiment Value(s-1) Basis for Value Estimation 
k1 Formation of enzyme-substrate complex 
by substrate recruitment of free enzyme; 





Formation of the enzyme-substrate complex from free enzyme and substrate 
molecules with weak valence chemical bonds is much easier than formation and 
breakage of strong covalent chemical bonds as in k3 i.e. k1 >> k3. 
 
k2 Formation of free enzyme by substrate 
release from enzyme-substrate complex; 
involves breaking weak valence chemical 
bonds 
 
10E-6  Release of substrate from enzyme-substrate complex is similar to, but occurs less 
readily than, association of free enzyme and substrate molecules in k1.  
 
k3 Formation of enzyme-product complex 
from enzyme-substrate complex; 
involves breaking and forming strong 
covalent chemical bonds  
 
17.8E-9 Obtained from literature [2] i.e. seed parameter from experimental validation; this 
is used as point of reference for estimating other ki's.   
 
k4 Formation of enzyme-product complex 
from enzyme-substrate complex; 
involves breaking and forming strong 
covalent chemical bonds  
 
10E-13 Backward reaction of enzyme-substrate complex formation from enzyme-
product complex is much smaller than forward reaction in order for overall 
pathway to proceed forward i.e. k4 << k3. 
 
k5 Formation of free enzyme by product 
release from enzyme-product complex; 
involves breaking weak valence chemical 
bonds 
 
10E-4 Release of product from enzyme-product complex is similar to, but occurs more 
readily than, association of free enzyme and substrate molecules in k1.  
  
k6 Formation of the enzyme-product 
complex; involves forming weak valence 
chemical bonds 
 
0 Formation of enzyme-product complex from free enzyme and product molecules 
is negligible based on classical Michaelis-Menten assumptions; may also be 
interpreted as consequence of enzyme specificity.   
   
k7 Formation of the enzyme-inhibitor 
complex; involves forming weak valence 
chemical bonds 
 
10E-7 The competitive inhibition model assumes reversible binding of free enzyme and 
inhibitor molecules that involves weak valence chemical bonds; enzyme-
inhibitor affinity is a function of molecular similarity between substrate and 
inhibitor molecules.  Here, enzyme-inhibitor affinity is considered to be less than 
enzyme-substrate affinity i.e. k7 < k1.   
 
k8 Formation of free enzyme by inhibitor 
release; involves breaking weak valence 
chemical bonds 
 
10E-7 Dissociation of enzyme-inhibitor complex assumed to occur at same rate as 
association.   
 
Eo Total enzyme concentration 10E-7 By Michaelis-Menten assumptions, enzyme is saturated, so this value should be 
>> Cer and DHCer from Table 1.  
V. DISCUSSION 
There is a considerable disparity between interpolated Cer 
experimental data and the simulation results derived from 
classical Michaelis-Menten kinetics. Simulation results do 
agree with the physical expectation that in an enzymatic 
system, the concentration of substrate and product over 
time are related by an inverse trend. However, additional 
experimental data (not presented) indicated that DHCer 
undergoes an initial decrease followed by a steady 
increase after 3 hours real-time later, which is not shown 
by simulation; the nonlinear dynamics of the interpolated 
experimental data are not mirrored in the simulated 












Figure 4. Cubic Spline Interpolation and Simulation of 
Ceramide-16 and DHCeramide-16 species. Left-hand 
(Ceramide) axis is on the scale of (0.95 to 1.2)E-10 pmol/mg. 
Right-hand (DHCeramide) axis is on the scale of 4.604E-11 
pmol/mg. X-axis (seconds) is on the scale of 0 to 2.5E4 seconds. 
 
As such, the classical Michaelis-Menten linear model 
explored in this study does not sufficiently simulate the 
dynamic reactions of DHCer and Cer in the ceramide de 
novo synthesis pathway catalyzed by the enzyme 
dihydroceramide desaturase.   
 
Parameter estimation is one major issue in this study.  
Model parameters, specifically reaction rate constants 
{ki’s} and total enzyme concentration [Eo], were 
estimated based on limited numerical data from literature 
reviews and basic biochemical assumptions.  Reaction 
rates were assumed constant throughout the simulation.  
However, reaction rates in the ceramide de novo synthesis 
pathway have been shown to slowly change with time by 
Hanada [10].  Ideally, a set of dynamic rate values should 
be derived for the model to maximize its consistent 
accuracy with time. Because parameter values are not 
exact, a sensitivity analysis must be performed to identify 
which rate constants are most important for governing 
system behavior.  It is expected that k3, the rate of 
conversion of the enzyme-substrate [ES] to the enzyme-
product [EP] complex, will be most sensitive to 
perturbation, while the rate constant for the reverse 
reaction, k4, will be the least sensitive to ensure that the 
transition from substrate to product proceeds forward.   
 
Another limitation is the assumption that DHSM was the 
sole inhibitor of the dihydroceramide desaturase reaction. 
In reality, more molecules also inhibit this reaction, and 
their consideration may be necessary to create an accurate 
model.  In addition, there is some anecdotal evidence that 
dihydroceramide desaturase acts on multiple molecules 
containing an unsaturated C-C bond [10-13]. Due to this the 
fundamental Michaelis-Menten assumption that 
dihydroceramide desaturase is saturated with DHCer and 
Cer may be violated.  
 
While the model developed herein is not perfect, it is a 
viable starting point for modeling the action of 
dihydroceramide desaturase. Once this model is 
perfected, it may be adapted directly to modeling other 
enzymes in the ceramide de novo synthesis pathway, and 
finally the models of each enzyme may be combined to 
create a complete pathway model.  
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